ClinicalTrials.gg
RecruitingNCT07258407Updated May 29, 2026

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

A Phase 1/2 interventional study of TD001 in Metastatic Castration-Resistant Prostatic Cancer, sponsored by T.O.A.D. Oncology SA. Recruiting at 7 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by T.O.A.D. Oncology SA · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France — 10 open to participants now, 13 under way, 4 of them phase 3. Prostatic Neoplasms, Castration-Resistant · France.

Planned enrollment
10th of 19
180 · median 180
Started
2026
with 1 other
Phase 1/2
5 of 19
4 open now
Primary completion
2028-03
later than 5 of 12 live
Registered
18th of 19
by date
Lead sponsor
1 of 19
T.O.A.D. Oncology SA

Among the 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 5 of the 12 other live ones, and was the 18th registered.

Prostatic Neoplasms, Castration-Resistant

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

10 of the 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).

Read the detailed description

This is a first-in-human, open-label, multicenter Phase 1/2 study with a dose escalation part to determine recommended Phase 2 doses (RP2Ds) of TD001 for further evaluation in an expansion part of the study. Multiple dosing schedules may be evaluated. The safety and preliminary efficacy endpoints of this study will support dose optimization in this patient population.

03

Conditions studied

  • Metastatic Castration-Resistant Prostatic Cancer

Keywords

  • CRPC
  • PSMA
  • prostate-specific membrane antigen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must fully understand the study requirements and voluntarily sign .
  • PSMA-expressing CRPC with documented progression based on serum PSA, 1.1 with PCWG3, and/or bone disease.
  • At least one measurable metastatic lesion per RECIST 1.1.
  • Adequate organ function.
  • Prior orchiectomy and/or ongoing androgen deprivation therapy.
  • Prior treatment with at least one androgen receptor pathway inhibitor (ARPI) drug.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, or hemi-body irradiation, within 6 months before treatment.
  • Systemic anticancer therapy including an agent within 28 days before treatment.
  • Known to the components of TD001, its analogs, or .
  • Current dyspnea at rest, other disease requiring continuous oxygen therapy, or history of pneumonitis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Dose escalation

    Sequential groups of participants receive TD001 at escalating doses

    Drug: TD001

  • Experimental
    RP2D dose expansion

    Groups of participants receive TD001 at the recommended Phase 2 doses (RP2Ds)

    Drug: TD001

Interventions

  • DrugTD001

    Intravenous (IV) infusion at protocol-defined doses and schedules until disease progression or other reason to end treatment

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (dose escalation)

    Number of participants with dose-limiting toxicity; incidence of adverse events (AEs), serious AEs (SAEs), abnormal laboratory parameters, TD001 discontinuation or modification due to AEs, as assessed by CTCAE v6.0

    Time frame: Treatment + follow-up (estimated 9 months)

  2. Recommended Phase 2 doses (dose escalation)

    Incidence of AEs, SAEs, abnormal laboratory parameters, TD001 discontinuation or modification due to AEs, as assessed by CTCAE v6.0

    Time frame: Treatment + follow-up (estimated 9 months)

  3. Safety/tolerability - incidence of AEs, SAEs, abnormal laboratory parameters (dose escalation + expansion)

    AEs, SAEs, abnormal laboratory parameters by type, severity, and relatedness as assessed by CTCAE v6.0

    Time frame: Treatment + follow-up (estimated 21 months)

  4. Safety/tolerability - incidence of TD001 discontinuation or modification due to AEs (dose escalation + expansion)

    AEs by type, severity, and relatedness as assessed by CTCAE v6.0

    Time frame: Treatment + follow-up (estimated 21 months)

Secondary outcomes

  1. Plasma PK - AUC

    Area under the concentration-time curve for total ADC, total antibody, and unconjugated payload

    Time frame: Estimated 6-8 months

  2. Plasma PK - AUClast

    Area under concentration-time curve from time zero to the last measurable concentration for total ADC, total antibody, and unconjugated payload

    Time frame: Estimated 6-8 months

  3. Plasma PK - AUCtau

    Area under concentration-time curve from time zero to the end of the dosing interval for total ADC, total antibody, and unconjugated payload

    Time frame: Estimated 6-8 months

  4. Plasma PK - Cmax

    Maximum concentration for total ADC, total antibody, and unconjugated payload

    Time frame: Estimated 6-8 months

  5. Plasma PK - Tmax

    Time to maximum concentration for total ADC, total antibody, and unconjugated payload

    Time frame: Estimated 6-8 months

  6. Plasma PK - T1/2

    Terminal elimination half-life for total ADC, total antibody, and unconjugated payload

    Time frame: Estimated 6-8 months

  7. Plasma PK - Ctrough

    Trough concentration for total ADC, total antibody, and unconjugated payload

    Time frame: Estimated 6-8 months

  8. PSA50 response rate

    ≥50% PSA decrease from baseline, per PCWG3

    Time frame: Treatment (estimated 8 months)

  9. Overall response rate

    Best response of CR or PR per PCWG3-modified RECIST 1.1

    Time frame: Treatment (estimated 8 months)

  10. PSA progression-free survival

    Per PCWG3

    Time frame: Treatment + follow-up (estimated 21 months)

  11. Radiographic progression-free survival

    per PCWG3-modified RECIST 1.1

    Time frame: Treatment + follow-up (estimated 21 months)

  12. Duration of response

    For PSA and radiographic response

    Time frame: Treatment + follow-up (estimated 21 months)

  13. Disease control rate

    Best response of CR, PR or SD

    Time frame: Treatment (estimated 8 months)

  14. Overall survival

    Time frame: Treatment + follow-up (estimated 21 months)

  15. Immunogenicity - prevalance and incidence of ADAs

    ADAs against TD001 prior to first dose and at any time on treatment

    Time frame: Treatment period + follow-up (estimated 9 months)

07

Study locations

6 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Mar 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 2, 2025
StartActual
Jan 30, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2029
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07258407
Lead sponsor
T.O.A.D. Oncology SA
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Jan 30, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
May 29, 2026

Study contacts

TOAD Clinical Operations
Contact
contact@toadonco.com
41 41 556 64 01

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion